Journal Watch
-
Glucose challenge test (GCT) detects glucose metabolism disorders in PD
When glucose-based PD fluid is used, it can be a challenge to see if there are blood sugar issues. In 20 people on PD who did not have a history of diabetes, an initial GCT detected impaired glucose tolerance in eleven and diabetes mellitus in four. About 2 years later, twelve patients had glucose metabolism disorders—but none had diabetes.
Read the abstract » | (added 2015-05-09)
Tags:
-
Home hemodialysis needs you! Special Kidney International supplement.
A special supplement of Kidney International focuses on how to implement home hemodialysis, from policies and procedures to equipment, recruitment, safety, prescription, staffing, and more—from global experts. Don't miss it!
Read the abstract » | (added 2015-05-09)
Tags: Home dialysis
-
Education can change negative nurse attitudes toward home dialysis
In-center HD nurses tend to prefer…in-center HD. But, their negative attitudes toward home treatments can be modified, a new study shows. In Canada, a 3-hour educational session with CE credits on the benefits of home treatments, myths about patient eligibility, costs, and a testimonial video did the trick.
Read the abstract » | (added 2015-05-09)
Tags:
-
Dosage of Tamiflu® for people on PD
A new study finds that a single, 75mg dose of oseltamivir may be enough for people on PD who don’t have residual kidney function. The more residual function people had, the more efficiently the drug was removed—so more was needed for an optimal response.
Read the abstract » | (added 2015-05-09)
Tags:
-
ACTIVE trial of extended dialysis described
A Clinical Trial of IntensiVE (ACTIVE) Dialysis is a randomized trial of extended (24+ hours) or standard (12-18 hours) of weekly HD for 12 months, looking at quality of life, left ventricular mass, and safety. The study has 200 participants from Australia, China, Canada, and New Zealand, meeting the planned recruitment target. The trial is registered at clinicaltrials.gov (NCT00649298).
Read the abstract » | (added 2015-04-10)
Tags:
-
Maximum ultrafiltration rate as a measure of optimal HD
Dialysis removes both wastes and water. Yet, while we have measures for waste removal, we have no marker for water—even though, in the short run, it is more important for patient health and well-being. Dr. Agar proposes a maximum ultrafiltration rate.
Read the abstract » | (added 2015-04-10)
Tags:
-
Nurses may be a barrier to extended in-center HD treatments
In a UK study to assess the feasibility of recruiting patients for a trial of 6-hour HD vs. 4-hour, 56 nurses were polled about their attitudes. While 95% of national non-nurse healthcare providers felt that the longer treatments were clinically helpful, just 42% of nurses agreed. And, while 75% of the non-nurses felt that longer HD treatments were well-tolerated, only 45% of nurses thought so—while 83% of nurses were concerned about the impact of the longer treatments on scheduling shifts.
Read the abstract » | (added 2015-04-10)
Tags:
-
Biocompatible PD fluid reduces cell death due to inflammation
In time, the peritoneum (just one cell layer thick) can wear out when used for PD. A new study finds that peritoneal cells in petri dishes bathed in standard PD fluid were more likely to die due to inflammation caused by glucose. But, cells bathed in biocompatible fluids were protected from the damage. In humans, this means that the peritoneum may last longer.
Read the abstract » | (added 2015-04-10)
Tags:
-
Icodextrin reduces PD failure and boosts survival
In a prospective trial of 306 incident PD patients between 2007 and 2011, those who used icodextrin were significantly more likely to continue with PD and more likely to live longer than those who used standard PD fluid.
Read the abstract » | (added 2015-04-10)
Tags:
-
Biocompatible PD fluids are cost-effective (in capitated systems…)
In Australia, where the cost of hospitalization is of concern to the National Healthcare System, one group of PD patients was given biocompatible PD fluid, while a control group received standard PD fluid. After 2 years, the more costly biocompatible fluid created significant cost savings due to reduced peritonitis and hospital stays.
Read the abstract » | (added 2015-04-10)
Tags: